论文部分内容阅读
目的:研讨血脂指标值对瑞舒伐他汀治疗眼脸黄色瘤应用成效的作用.方法:选择2018年3月-2021年3月我院门诊收治的眼睑黄色瘤患者50名入组进行研究,对患者的血清胆固醇指标进行测量后把胆固醇高的一组患者作为实验组,把总胆固醇指标值正常的25名对象作为参照组,两组对象都给予瑞舒伐他汀进行口服,进行诊治一年以后,对眼睑黄色瘤的面积大小、厚度多少、数量变化进行观察,并进行组间比较.结果:诊治期间发生转氨酶轻微上升有两名,轻度腹部发涨1名,没有停止服用瑞舒伐他汀钙片,对转氨酶轻微升高的患者给予口服多烯磷脂酰胆碱3“,”Objective: To discuss the effect of blood lipid index on the application effect of resuvastatin in the treatment of ocular yeloma. Methods: choose March 2018 to March 2021 outpatient 50 eyelid yellow tumor patients for study, patients with serum cholesterol high cholesterol as experimental group, 25 objects with normal total cholesterol index as a reference group, both groups are given reshuvastatin oral, after diagnosis and treatment for a year, the area size, thickness and number of eyelid yellow tumor observed, and group comparison. Results: Two transaminase rose slightly during diagnosis and treatment, 1 mild abdominal rise, resuvastatin calcium tablet was not stopped for 30 days, and liver function returned to normal. No other adverse symptoms occurred; the values of blood lipid indexes before and after treatment were shown in Table 1. Significant reductions in lipid indicators in both groups, and the levels of total cholesterol and LDL reductions were statistically different compared with the reference group, ( P ＜ 0. 05 ) . In both groups, the experimental group was 92. 00％, significantly higher than 44. 00％ of the reference group, and varied significantly between groups, ( P ＜ 0. 05 ) . Conclusion: Regardless of whether eyelid yeloma has hypercholesteraemia, reshuvastatin can achieve good clinical treatment with hypercholesteraemia.